These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

287 related articles for article (PubMed ID: 18587556)

  • 21. [Impact of immunotherapy in metastatic kidney cancer in Germany after introduction of new target therapy--results of a telephone survey of the German Society of Immuno- and Targeted Therapy (DGFIT)].
    Siebels M; Staehler M; Hegele A; Varga Z; Oberneder R; Doehn C; Heinzer H;
    Aktuelle Urol; 2010 Mar; 41(2):122-30. PubMed ID: 19937556
    [TBL] [Abstract][Full Text] [Related]  

  • 22. First-line therapy for treatment-naive patients with advanced/metastatic renal cell carcinoma: a systematic review of published randomized controlled trials.
    Takyar S; Diaz J; Sehgal M; Sapunar F; Pandha H
    Anticancer Drugs; 2016 Jun; 27(5):383-97. PubMed ID: 26886011
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Metastatic renal cell cancer treatments: an indirect comparison meta-analysis.
    Mills EJ; Rachlis B; O'Regan C; Thabane L; Perri D
    BMC Cancer; 2009 Jan; 9():34. PubMed ID: 19173737
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Sequence therapy in patients with metastatic renal cell carcinoma: comparison of common targeted treatment options following failure of receptor tyrosine kinase inhibitors.
    Busch J; Seidel C; Kempkensteffen C; Johannsen M; Wolff I; Hinz S; Magheli A; Miller K; Grünwald V; Weikert S
    Eur Urol; 2011 Dec; 60(6):1163-70. PubMed ID: 21802830
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sequential treatment with sorafenib and sunitinib in metastatic renal cell carcinoma: clinical outcomes from a retrospective clinical study.
    Kontovinis L; Laschos K; Karadimou A; Andreadis C; Bamias A; Paraskevopoulos P; Dimopoulos M; Papazisis K
    Med Oncol; 2012 Jun; 29(2):750-4. PubMed ID: 21279702
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy of targeted therapy in patients with renal cell carcinoma with pre-existing or new bone metastases.
    Zołnierek J; Nurzyński P; Langiewicz P; Oborska S; Waśko-Grabowska A; Kuszatal E; Obrocka B; Szczylik C
    J Cancer Res Clin Oncol; 2010 Mar; 136(3):371-8. PubMed ID: 19711099
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Efficacy of multikinase inhibitors in the treatment of advanced renal cell cancer. A snapshot].
    Kuczyk M; Kruck S; Merseburger AS
    Urologe A; 2007 May; 46(5):504-8, 510. PubMed ID: 17437075
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Sunitinib, sorafenib and mTOR inhibitors in renal cancer.
    Radulovic S; Bjelogrlic SK
    J BUON; 2007 Sep; 12 Suppl 1():S151-62. PubMed ID: 17935273
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Sequential therapies with sorafenib and sunitinib in advanced or metastatic renal cell carcinoma.
    Herrmann E; Marschner N; Grimm MO; Ohlmann CH; Hutzschenreuter U; Overkamp F; Groschek M; Blumenstengel K; Pühse G; Steiner T
    World J Urol; 2011 Jun; 29(3):361-6. PubMed ID: 21461939
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Frequent dose interruptions are required for patients receiving oral kinase inhibitor therapy for advanced renal cell carcinoma.
    La Vine DB; Coleman TA; Davis CH; Carbonell CE; Davis WB
    Am J Clin Oncol; 2010 Jun; 33(3):217-20. PubMed ID: 19745694
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Second line treatment of metastatic renal cell carcinoma: The Institut Gustave Roussy experience with targeted therapies in 251 consecutive patients.
    Levy A; Menard J; Albiges L; Loriot Y; Di Palma M; Fizazi K; Escudier B
    Eur J Cancer; 2013 May; 49(8):1898-904. PubMed ID: 23490648
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Treatment options for metastatic renal cell carcinoma: a review.
    Athar U; Gentile TC
    Can J Urol; 2008 Apr; 15(2):3954-66. PubMed ID: 18405442
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Influence of bevacizumab, sunitinib and sorafenib as single agents or in combination on the inhibitory effects of VEGF on human dendritic cell differentiation from monocytes.
    Alfaro C; Suarez N; Gonzalez A; Solano S; Erro L; Dubrot J; Palazon A; Hervas-Stubbs S; Gurpide A; Lopez-Picazo JM; Grande-Pulido E; Melero I; Perez-Gracia JL
    Br J Cancer; 2009 Apr; 100(7):1111-9. PubMed ID: 19277038
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Targeted therapies in metastatic renal cancer in 2009.
    Bastien L; Culine S; Paule B; Ledbai S; Patard JJ; de la Taille A
    BJU Int; 2009 May; 103(10):1334-42. PubMed ID: 19338565
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Evaluation of the management of metastatic renal cell carcinoma in the era of targeted therapies. retrospective clinical study over six years].
    Latteux G; Lebdai S; Hoarau N; Abadie-Lacourtoisie S; Delva R; Chautard D; Azzouzi AR; Bigot P
    Prog Urol; 2013 Mar; 23(3):184-94. PubMed ID: 23446283
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A cross-over response to sequential use of sunitinib after sorafenib in a patient with metastatic renal cell carcinoma.
    Richards TM; Plowman PN; Reznek R; Ball SA
    Clin Oncol (R Coll Radiol); 2009 Oct; 21(8):633-4. PubMed ID: 19380217
    [No Abstract]   [Full Text] [Related]  

  • 37. Metastatic sarcomatoid renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy.
    Golshayan AR; George S; Heng DY; Elson P; Wood LS; Mekhail TM; Garcia JA; Aydin H; Zhou M; Bukowski RM; Rini BI
    J Clin Oncol; 2009 Jan; 27(2):235-41. PubMed ID: 19064974
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Targeted therapy for metastatic renal cell carcinoma.
    Patel PH; Chaganti RS; Motzer RJ
    Br J Cancer; 2006 Mar; 94(5):614-9. PubMed ID: 16465192
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Sorafenib in patients with metastatic renal cell carcinoma refractory to either sunitinib or bevacizumab.
    Garcia JA; Hutson TE; Elson P; Cowey CL; Gilligan T; Nemec C; Dreicer R; Bukowski RM; Rini BI
    Cancer; 2010 Dec; 116(23):5383-90. PubMed ID: 20806321
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Safety and efficacy of the combination of erlotinib and sirolimus for the treatment of metastatic renal cell carcinoma after failure of sunitinib or sorafenib.
    Flaig TW; Costa LJ; Gustafson DL; Breaker K; Schultz MK; Crighton F; Kim FJ; Drabkin H
    Br J Cancer; 2010 Sep; 103(6):796-801. PubMed ID: 20823888
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.